Clinical trials: Oral Cancers
Non-Hodgkin Lymphoma, Neoplasms
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors.
- Trial name
- NCT00503451
- Testing
- LBH589
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Uterine Fibroids
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time)…
- Trial name
- NCT02655237
- Testing
- Relugolix, Leuprorelin
- Where
- 25 sites in Japan
- Volunteers
- 281 people
- Sponsor
- Takeda
Acute Promyelocytic Leukemia
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene PML-RARA. We have formulated an oral preparation of As2O3 (oral-As2O3), and shown that it is efficacious for APL in R1, inducing CR2 in…
- Trial name
- NCT03624270
- Testing
- Oral arsenic Trioxide, ATRA and ascorbic acid
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Thyroid Cancer
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC)…
- Trial name
- NCT00784303
- Testing
- Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Inc.
Stomatitis, Radiation Effects
Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx
The purpose of this study is to compare the effectiveness and safety of benzydamine hydrochloride 0.15% oral rinse to a vehicle oral rinse in the treatment of radiation-induced oral mucositis, and to compare the care normally…
- Trial name
- NCT00051441
- Testing
- Benzydamine Hydrochloride 0.15% Oral Rinse
- Volunteers
- 605 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Cancer T1-N0 or T2-N0 of the Oral Cavity
Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)
This is a single-center pilot study of open-label, non-randomized interventional research based on the outpatient management of 30 patients with T1-N0 or T2-N0 cancer in the oral cavity or oropharynx.
- Trial name
- SACO (NCT03545256)
- Testing
- outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Tumors, Non Hodgkin's Lymphoma
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.
- Trial name
- NCT00323934
- Testing
- MGCD0103
- Where
- 3 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Mirati Therapeutics Inc.
Tongue Cancer
Anterolateral Thigh Myofascial Fat Composite Flap for Reconstruction of Hemiglossectomy Defects in Obese Patients With Tongue Cancer
Tongue cancer is a common malignant tumor in oral and maxillofacial surgery. After surgical resection, it is often accompanied by hemitongue defect.
- Trial name
- ALT-MF (NCT07682467)
- Testing
- The anterolateral femoral myofascial fat composite flap (ALT-MF) repairs tongue defects in patients with tongue cancer
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oropharyngeal Cancer
Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance
The objective of this research is to perform a pilot study on patients undergoing laryngoscopy for diagnostic and tumor staging purposes (for pharyngeal or laryngeal cancer) in which intraoperative CT imaging will be performed…
- Trial name
- NCT02405000
- Testing
- Intraoperative CT imaging
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Oral Mucositis, Lymphoma
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell…
- Conditions
- Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
- Trial name
- Capella (NCT05493800)
- Testing
- MIT-001, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Relapsed and Refractory Multiple Myeloma
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD) and disease response of Ixazomib administered orally in participants with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT00932698
- Testing
- Ixazomib
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Colorectal Cancer
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Thalidomide may stop the growth of colorectal cancer by stopping blood flow to the tumor. Giving thalidomide after surgery may kill any remaining tumor cells.
- Trial name
- NCT00019747
- Testing
- thalidomide, adjuvant therapy
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hemifacial Microsomia, Mucormycosis
Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.
This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects.
- Conditions
- Hemifacial Microsomia, Mucormycosis, Oral Squamous Cell Carcinoma, Microgenia
- Trial name
- 3DFACE (NCT07654647)
- Testing
- Patient-specific titanium implants for facial reconstruction
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Latakia University
Locally Advanced or Metastatic Solid Tumors
Oral Bioavailability and Mass Balance Trial With Pimasertib
This is a Phase 1, open-label, single centered trial to evaluate the mass balance, bioavailability and metabolism of pimasertib in cancer subjects with locally advanced or metastatic solid tumors.
- Trial name
- NCT01713036
- Testing
- Pimasertib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer
Telmisartan in Prostate Cancer
The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
- Trial name
- NCT06168487
- Testing
- Telmisartan, Standard of Care Regimen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tyler J Curiel
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Oral Squamous Cell Carcinoma
Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy
Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities.
- Trial name
- OSCC (NCT05150509)
- Testing
- Oral Squamous Cell Carcinoma
- Where
- 2 sites in Bangladesh
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- DR. MALA KHAN
Sarcoma
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00033709
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center